Potential savings without compromising the quality of care

International Journal of Clinical Practice

Volumn 63, Issue 9, 2009, Pages 1320-1326

  Norman, C ^a   Zarrinkoub, R ^a   Hasselstrom J ^a   Godman, B ^b   Granath, F ^c   Wettermark, B ^a,c  

^a STOCKHOLM COUNTY COUNCIL   (Sweden)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATORVASTATIN; BENDROFLUMETHIAZIDE; CANDESARTAN; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GLIBENCLAMIDE; HEMOGLOBIN A1C; HUMAN INSULIN; HYDROCHLOROTHIAZIDE; INSULIN ASPART; INSULIN LISPRO; LOSARTAN; METFORMIN; METOPROLOL; RAMIPRIL; SIMVASTATIN; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; COST CONTROL; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE MARKER; DRUG COST; DRUG USE; ECOLOGY; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH CENTER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MEDICAL RECORD; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY HEALTH CARE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; CLINICAL TRIAL; ECONOMICS; MULTICENTER STUDY; SWEDEN;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; COST SAVINGS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; GUIDELINE ADHERENCE; HEALTH EXPENDITURES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOGLYCEMIC AGENTS; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; QUALITY OF HEALTH CARE; SIMVASTATIN; SWEDEN;

EID: 68949197590     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02129.x     Document Type: Article

References (48)

1. Sjöqvist F, Bergman U, Dahl ML et al. Drug and therapeutics committees: a Swedish experience. WHO Drug Inf 2002 16 : 207 213.
2. Wettermark B, Godman B, Andersson K, Gustafsson LL, Haycox A, Bertele V. Recent national and regional drug reforms in Sweden - implications for pharmaceutical companies in Europe. Pharmacoeconomics 2008 26 : 537 550.
3. Godman B, Wettermark B, Hoffmann M, Andersson K, Haycox A, Gustafsson LL. Swedish experience in ambulatory care with multifaceted national and regional drug reforms and initiatives: global relevance. Expert Rev Pharmacoecon Outcomes Res 2009 9 : 65 83.
4. Usher-Smith JA, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting. Int J Clin Pract 2007 61 : 15 23.
5. Beishon J, McBride T, Scharaschkin A et al., National Audit Office. Prescribing Costs in Primary Care. 10 May 2007 - http://www.nao.ork.uk/ publications/0607/prescribing-costs-in-primary-c.aspx http://www.nao.org.uk/ publications/0607/prescribing-costs-in-primary-c.aspx (accessed May 2007).
6. Godman B, Haycox A, Schwabe U, Joppi R, Garattini S. Having your cake and eating it: Office of Fair Trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics 2008 26 : 91 8.
7. Matchar DB, McCrory DC, Orlando LA et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008 148 : 16 29.
8. Hedberg N, Jacob J. A Review of Medicines for Lowering Blood Pressure - a Summary. Solna : Pharmaceuticals Benefits Board, 2008. http://www.tlv.se/ upload/Genomgangen/review-blood-pressure.pdf, and http://www.tlv.se/Upload/ Genomgangen/summary-blood-pressure.pdf (accessed March 2008).
9. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008 358 : 1547 1559.
10. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005 366 : 1267 1278.
11. Zhou Z, Rahme E, Pilote L. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J 2006 151 : 273 281.
12. Ward S, Lloyd Jones M, Pandor A et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007 11 : 1 160, iii-iv.
13. Grol R, Wensing M. What drives change? Barriers to and incentives for achieving evidence-based practice. Med J Aust 2004 180 : S57 60.
14. Hibble A, Kanka D, Pencheon D, Pooles F. Guidelines in general practice: the new Tower of Babel? BMJ 1998 317 : 862 863.
15. Haaijer-Ruskamp FM, Hoven JL, Mol PGM. A Conceptual Framework for Constructing Prescribing Quality Indicators: a Proposal. DURQUIM: Drug Utilization Quality Indicator Meeting. Mechelen, Belgium : WHO Europe, 2004.
16. Hoven JL, Haaijer-Ruskamp FM, Vander Stichele RH, DURQUIM Scientific Committee. Indicators of prescribing quality in drug utilisation research: report of a European meeting (DURQUIM, 13-15 May 2004). Eur J Clin Pharmacol 2005 60 : 831 834.
17. Smith PC, York N. Quality incentives: the case of UK General Practitioners. Health Aff 2004 23 : 112 118.
18. Roland M. Linking physicians' pay to the quality of care - a major experiment in the United Kingdom. N Eng J Med 2004 351 : 1448 1454.
19. Doran T, Fullwood C, Gravelle H et al. Pay-for-performance programs in family practices in the United Kingdom. N Engl J Med 2006 355 : 375 384.
20. Schmacke N, Lauterberg J. Criticism of new German chronic disease management is unfair. BMJ 2002 325 : 971.
21. Busse R, Schreyögg J, Henke KD. Regulation of pharmaceutical markets in Germany; improving efficiency and controlling expenditures? Int J Health Plann Manage 2005 20 : 329 349.
22. Donabedian A. The quality of care. How can it be assessed? JAMA 1988 260 : 1743 1748.
23. Mant J. Process versus outcome indicators in the assessment of quality of health care. Int J Qual Health Care 2001 13 : 475 480.
24. Crombie IK, Davies HTO. Beyond health outcomes: the advantages of measuring process. J Eval Clin Pract 1998 4 : 31 8.
25. Guidelines for ATC Classification and DDD Assignment. Oslo : WHO Collaborating Centre for Drug Statistics Methodology, 2006. http://www.whocc.no/ atcddd/ (accessed June 2009).
26. Wettermark B, Pehrsson A, Jinnerot D, Bergman U. Drug utilisation 90% profiles - a useful tool for quality assessment of prescribing in primary health care in Stockholm. Pharmacoepidemiol Drug Saf 2003 12 : 499 510.
27. Socialstyrelsen. Nationella riktlinjer för hjärtsjukvård. Beslutsstöd för Prioriteringar in Swedish (National Guidelines for Cardiovascular Diseases 2008 Established by National Board of Health and Welfare). Stockholm : The Swedish National Board of Health and Welfare (Socialstyrelsen), 2008.
28. Socialstyrelsen. Nationella riktlinjer för diabetes. In Swedish. (National Guidelines for Management and Treatment of Diabetes Mellitus). Stockholm : The Swedish National Board of Health and Welfare (Socialstyrelsen), 1999.
29. Engfeldt P, Popa C, Bergensand P et al. Kvalitetsarbete kring läkemedelsförskrivning i primärvården. Nytt databasprogram underlättar uppföljning av läkemedelsbehandling. Läkartidningen 2001 50 : 5767 5771.
30. World Health Organization. International Classification of Diseases and Related Health Problems - Tenth Version (ICD-10). http://www.who.int/ classification/icd/en (accessed June 2009).
31. Carrin G. Drug prescribing: a discussion of its variability and (ir)rationality. Health Policy 1987 7 : 73 94.
32. Baker D, Klein R. Explaining outputs of primary health care: population and practice factors. BMJ 1991 303 : 225 229.
33. Steffensen FH, Sorensen HT, Olesen F. Diffusion of new drugs in Danish general practice. Fam Pract 1999 16 : 407 413.
34. Ashworth M, Armstrong D. The relationship between general practice characteristics and quality of care: a national survey of quality indicators used in the UK Quality and Outcomes Framework, 2004-5. BMC Fam Pract 2006 7 : 68.
35. Khunti K, Gadsby R, Millett C, Majeed A, Davies M. Quality of diabetes care in the UK: comparison of published quality-of-care reports with results of the Quality and Outcomes Framework for Diabetes. Diabet Med 2007 24 : 1436 1441.
36. Grimsmo A, Hagman E, Faikø E, Matthiessen L, Njálsson T. Patients, diagnoses and processes in general practice in the Nordic countries. An attempt to make data from computerised medical records available for comparable statistics. Scand J Prim Health Care 2001 19 : 76 82.
37. Lawrenson R, Williams T, Farmer R. Clinical information for research; the use of general practice databases. J Public Health Med 1999 21 : 299 304.
38. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005 58 : 323 337.
39. Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int J Clin Pract 2008 62 : 480 484.
40. Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract 2008 62 : 76 87.
41. Salzer MS, Nixon CT, Schut LJA, Karver MS, Bickman L. Validating quality indicators. Quality as relationship between structure, process, and outcome. Eval Rev 1997 21 : 292 309.
42. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 853.
43. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998 352 : 854 865.
44. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007 356 : 2457 2471.
45. Barter PJ, Caulfield M, Eriksson M et al., for the ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007 357 : 2109 2122.
46. Guyatt G, Rennie D. Users' Guide to the Medical Literature: Essentials of Evidence-Based Clinical Practice. Chicago, IL : AMA Press, 2002.
47. Prescott RJ et al. Factors that limit the quality, number and progress of randomised controlled trials: a review. Health Technol Assess 1999 3 : 1 143.
48. Wettermark B, Hammar N, Fored M et al. The new Swedish Prescribed Drug Register - opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007 16 : 726 735.